TOKYO, Oct. 12, 2023 /PRNewswire/ — After launching the 2D AI virtual anchor Ubi-chan at the Tokyo Game Show, Ubitus K.K. (hereinafter Ubitus), a cloud streaming pioneer, recently collaborated with NOWnews to release a highly realistic 24 hours nonstop AI anchor named ‘Ni Zhen’ in Taiwan.

Cloud Power: Developing Advanced AI Solutions
In an era of rapid digital technology advancement and information explosion, audiences prefer to absorb information quickly and efficiently. Ubitus offers powerful cloud computing capabilities that enable a large language model (Large Language Model) to automatically condense lengthy news content into concise news summaries by combining both text and images. With the help of AI speech recognition technology, the LLM calculates the appropriate lips movements for the AI anchor and pairs it with text-to-speech (Text to Speech) technology to deliver real-time news broadcasts from the cloud. By integrating multiple AI technologies, Ubitus is able to make the AI anchor’s responses more human-like, creating a realistic character movement while providing succinct news reporting. News summaries are usually grasped in just about 90 seconds.

The transformation of media industry by AI
The growing enthusiasm for AI technology has led to its application in various industries, including media. Unlike the AI anchors created by other providers, ‘Ni Zhen’ from NOWnews uses 4K high-quality real-life videos for training, enabling AI to learn full-body language and lips movements. This technology enhances ‘Ni Zhen’s’ facial expressions, making her presentation more natural and lively. By automating daily news scripts, ‘Ni Zhen’ can deliver concise summaries and continuous 24-hour broadcasts to the audience. Ubitus offers powerful cloud computing capabilities, ensuring smooth real-time operation of this AI system and article summarization technology in the cloud. The AI anchor can also generate content in multiple languages simultaneously and utilize AI drawing tools to customize its appearance, providing the audience with an exquisite and immediate AI anchor viewing experience.

Wesley Kuo, CEO of Ubitus, expressed, ‘We are honored to successfully launch the AI anchor with NOWnews. By effectively leveraging AI to improve people’s lives, we seek to continuously develop suitable solutions to drive progress in various industries.’

24 hours live news link: https://www.youtube.com/@NOWnews-sp2di

About Ubitus

Ubitus operates the world’s best GPU virtualization technology and cloud streaming platform, and is dedicated to providing a superior user experience via its advanced technology. As long as users are connected to a broadband network, they can enjoy AAA gaming experience across various devices, such as smartphones, tablets, game consoles, smart TVs, and personal computers.

With innovative Game Cloud® technology, Ubitus is able to stream interactive media content with immersive experience on multi-devices for platform operators and digital content developers, while accelerating metaverse popularization with broad applications.

Leveraging the power of GPUs, Ubitus has ventured into AI development. Large language models (LLM), graph diffusion models, and other generative AI tools aim to provide innovative solutions for unique challenges across various industries.

Source : Ubitus utilizes the strength of computing power to bring innovative AI technology and audiovisual media solutions

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

ROSEN, A LEADING LAW FIRM, Encourages Discover Financial Services Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – DFS

Corporate News Media OutReach

Oct 12, 2023

Hong Kong Baptist University-led research discovers new therapeutic target for irritable bowel syndrome

New York, New York – Newsfile Corp. – October 11, 2023 – WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Discover Financial Services (NYSE: DFS) between February 21, 2019 and August 14, 2023, both dates inclusive (the “Class Period”) of the important October 31, 2023 lead plaintiff deadline.

SO WHAT: If you purchased Discover Financial common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Discover Financial class action, go to https://rosenlegal.com/submit-form/?case_id=7773 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than October 31, 2023. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Discover Financial maintained deficient risk management and compliance procedures; (2) as a result of the foregoing deficiencies, Discover Financial had, among other things, failed to comply with applicable student loan servicing standards, misclassified certain credit card accounts, overcharged customers, and failed to stem its ballooning credit card delinquency rate; (3) the foregoing issues, when they became known, would subject Discover Financial to significant financial exposure, regulatory scrutiny, and reputational harm; and (4) as a result, Discover Financial’s public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Discover Financial class action, go to https://rosenlegal.com/submit-form/?case_id=7773 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

——————————-

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
[email protected]
[email protected]
www.rosenlegal.com

The issuer is solely responsible for the content of this announcement.

https://platform.twitter.com/widgets.js

Source link

This content was prepared by Media OutReach. The opinions expressed in this article are the author's own and do not reflect the view of Siam News Network.

Musim Mas Achieves ISPO Certification for All Upstream Operations, Commits to Sustainable Palm Oil

CISION PR Newswire

Oct 12, 2023

Musim Mas’ Smallholders Program trains independent smallholders to implement good and sustainable agronomic practices and to obtain Indonesian Sustainable Palm Oil (ISPO) certification.

Through its Smallholders Program, Musim Mas also encourages smallholders to fulfill certification.

JAKARTA, Indonesia, Oct. 12, 2023 /PRNewswire/ — Palm oil and its derivatives have become essential commodities and a major contributor to Indonesia’s exports. However, the sector has been in the spotlight due to concerns over the risks of deforestation, forest degradation, and loss of biodiversity.

Musim Mas’ Smallholders Program trains independent smallholders to implement good and sustainable agronomic practices and to obtain Indonesian Sustainable Palm Oil (ISPO) certification.

To address the issue, the Indonesian government, through the Ministry of Agriculture, developed the Indonesian Sustainable Palm Oil (ISPO) certification standard in 2011 to ensure palm oil production in Indonesia is sustainable. ISPO certification is mandatory for all Palm Oil Plantation Business Actors and Planters. ISPO was also updated to include new benchmarks under Presidential Regulation 44 of 2020. This includes enhanced efforts to accelerate the reduction of carbon emissions, improve environmental management and social protection, and increase the competitiveness of Indonesian palm oil.

With its commitment to sustainability, Musim Mas Group achieved 100% ISPO certification for its 17 upstream subsidiaries last August.

"For Musim Mas, sustainability means responsibly providing high-quality and innovative palm oil products and derivatives. Together with stakeholders in this industry, we try to find the best solutions to address carbon gas emissions, biodiversity, and human rights, including workers’ rights. The ISPO certification that we received further strengthens our commitment to running our business following applicable laws," said Olivier Tichit, Director of Sustainability for Musim Mas Group.

Beyond its own operations, Musim Mas also supports independent smallholders. Smallholders make up around 41% of oil palm planted areas and have a deadline of 2025 to gain ISPO certification but often lack the know-how and resources to produce sustainably. To support them, Musim Mas leads Indonesia’s largest independent Smallholder Program to provide training on sustainable agricultural practices and encourage certification.

Rudman Simanjuntak, Manager of Independent Smallholder Musim Mas Group, explained, "Independent smallholders are an important group that must be included in making sustainable palm oil the norm. We encourage and assist them in fulfilling the criteria required in the certification process. Through Musim Mas’ Smallholder Program, we ensure that no one is left behind in our journey towards a more sustainable palm oil industry."

As of September 2023, Musim Mas’ Smallholders Program has trained over 41,900 independent smallholders throughout Indonesia. Of these, 1,959 farmers have successfully been ISPO certified.

Media contact:
First name: Reza Rinaldi
Last name: Mardja
Email: [email protected]
Business Phone Number: +62-811-606-3237

Source : Musim Mas Achieves ISPO Certification for All Upstream Operations, Commits to Sustainable Palm Oil

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Integra LifeSciences Holdings Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action – IART

Corporate News Media OutReach

Oct 12, 2023

New York, New York – Newsfile Corp. – October 11, 2023 – WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Integra LifeSciences Holdings Corporation (NASDAQ: IART) between March 11, 2019 and May 22, 2023, both dates inclusive (the “Class Period”), of the important November 13, 2023 lead plaintiff deadline.

SO WHAT: If you purchased Integra common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Integra class action, go to https://rosenlegal.com/submit-form/?case_id=19078 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than November 13, 2023. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period defendants made false statements and/or concealed that Integra had failed to take sufficient measures to remediate the violations identified by the U.S. Food and Drug Administration (“FDA”) in the November 2, 2018 Notice of Inspectional Observations on Form 483, the March 6, 2019 FDA issued warning letter, and the November 12, 2021 FDA issued Form 483. As a result of those deficiencies, since March 2018, all products manufactured in the Company’s manufacturing plant located in Boston, Massachusetts (the “Boston Facility”), including SurgiMend, PriMatrix, Revize, and TissueMend, had the potential for higher-than-permitted levels of endotoxin and would need to be recalled. Moreover, Integra was not making progress towards obtaining its premarket approval (“PMA”) indication for SurgiMend, in part, because the manufacturing site that would produce the PMA product, the Boston Facility, was in continued violation of the FDA standards that Integra failed to rectify years after the initial notice of the violations and as a result the facility had to be shutdown to correct those ongoing deficiencies. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Integra class action, go to https://rosenlegal.com/submit-form/?case_id=19078 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

——————————-

Contact Information:

The issuer is solely responsible for the content of this announcement.

https://platform.twitter.com/widgets.js

Source link

This content was prepared by Media OutReach. The opinions expressed in this article are the author's own and do not reflect the view of Siam News Network.

Suvoda Introduces Advanced Drug Optimization For IRT to Improve Accuracy of Clinical Trial Drug Supply Management

CISION PR Newswire

Oct 12, 2023

Greater Control Over Drug Supply Management Helps Sponsors Reduce Costs and Carbon Footprint

PHILADELPHIA, Oct. 12, 2023 /PRNewswire/ — Suvoda LLC, a global clinical trial technology company that specializes in complex studies in therapeutic areas like oncology, central nervous system (CNS), and rare disease, announced a new Advanced Drug Optimization feature as part of its latest Interactive Response Technology (IRT) release. This new functionality offers sponsors of clinical drug trials improved drug supply management, delivering cost savings and helping companies to reduce their carbon footprint.

Traditionally, drug supply strategies have relied on static quantities of initial drug shipments and buffers, often leading to excessive orders to ensure enough medication is available during a trial. Buffers, a common tool for ensuring adequate medication supply at sites, create average upper and lower limits for medication stock at all trial sites and automatically trigger medication orders if supplies hit the low limit.

Suvoda’s Advanced Drug Optimization feature is an innovative approach that allows drug supply managers to fine-tune their supply strategies by creating "advanced rules" that factor in enrollment variables, such as participant weight, projected screen failure rates, and treatment ratios. The result is more granular and dynamic supply forecasts, which may translate to significant cost savings. Further, by enabling more precise drug optimization, sponsors may cut back on packaging and shipping, which translates to a better carbon footprint score in support of corporate sustainability goals.

"Suvoda’s new enhancement is an example of how we listen to the needs of our customers and deliver tools that help our sponsors and partners," said Lisa Li, director of IRT product management with Suvoda. "We heard from drug supply managers that they were concerned about the impact of drug oversupply across the entire supply chain, including raw materials, manufacturing, storage, shipping, and packing materials. Helping study managers fine-tune supply can maximize trial resources and increase efficiencies."

The Advance Drug Optimization feature aligns with Suvoda’s mission to deliver purpose-built e-clinical solutions that give sponsors command over trials with complex drug supply management needs. Examples include trials with patient cohorts featuring large variations that can affect enrollment dosage, such as pediatric trials. Other trial designs that could benefit from this functionality include those involving high-cost drugs, high screen failure rates, and large trials with numerous subjects per site.

This enhancement also strengthens Suvoda’s partnership with N-SIDE, a deep tech company that empowers organizations in the clinical trials industry to make better decisions and optimize the use of critical resources. Together, Suvoda and N-SIDE seamlessly deliver integrated forecasting and supply-chain optimization to help studies reduce drug supply cost and wastage.

"As a Suvoda partner, we are excited about this feature. We’ve quantified the impact of this advanced functionality on hundreds of trials, and it generally reduces drug needs by more than 10 percent," said Amaury Jeandrain, vice president of strategy, life sciences, for N-SIDE. "Suvoda has always been committed to innovating on drug supply to ensure that its IRT solution continues to give sponsors the greatest amount of visibility and control possible. And, Advanced Drug Optimization gives us more tools to help our joint customers meet their drug supply needs in ways that better support their clinical trial and organizational goals."

Learn more about Suvoda IRT for clinical trials.

About Suvoda
Suvoda is a global clinical trial technology company specializing in complex, life-sustaining studies in therapeutic areas like oncology, central nervous system (CNS), and rare disease. Founded in 2013 by experts in eClinical technologies, Suvoda empowers clinical trial professionals to manage the most urgent moments in the most urgent trials through advanced software solutions delivered on a single platform. Headquartered outside Philadelphia, Suvoda also maintains offices in Portland, OR, Barcelona, Spain, Bucharest and Iasi, Romania, and Tokyo, Japan. The company’s Net Promoter Score (NPS) consistently exceeds the technology industry average, contributing to the company being selected by trial sponsors and CROs to support more than 1,000 trials across 80 countries. To learn more, visit suvoda.com and follow Suvoda on LinkedIn.

For information contact:

Mara Conklin, (847) 340-6823
[email protected]

Kathy Zoeller, (312) 485-2422
kathy@mattsonpr.com

Logo – https://mma.prnasia.com/media2/1759317/Suvoda_Logo.jpg?p=medium600

Source : Suvoda Introduces Advanced Drug Optimization For IRT to Improve Accuracy of Clinical Trial Drug Supply Management

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

CMA DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Comerica Incorporated Investors with Losses to Secure Counsel Before Important October 20 Deadline in Securities Class Action First Filed by the Firm – CMA

Corporate News Media OutReach

Oct 12, 2023

New York, New York – Newsfile Corp. – October 11, 2023 – WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Comerica Incorporated (NYSE: CMA) between February 9, 2021 and May 29, 2023, both dates inclusive (the “Class Period”), of the important October 20, 2023 lead plaintiff deadline in the securities class action commenced by the Firm.

SO WHAT: If you purchased Comerica securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Comerica class action, go to https://rosenlegal.com/submit-form/?case_id=16714 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than October 20, 2023. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made materially false and/or misleading statements and/or failed to disclose, among other things, that: (1) Comerica failed to provide meaningful oversight over the vendors to whom it contracted out day-to-day operations of the Direct Express program, a system through which it is contracted to provide federal benefits to millions of Americans without bank accounts; (2) as a result of violations in the day-to-day operations of Direct Express, including handling fraud disputes and allowing sensitive data to be handled out of a vendor’s office in Pakistan, Comerica was not in compliance with the Federal contract, and knew it was not in compliance; (3) Comerica knew and failed to disclose that it was in potential violation of Regulation E due to inadequate fraud prevention in the Direct Express program and responses to instances of fraud; and (4) as a result, Defendants’ statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Comerica class action, go to https://rosenlegal.com/submit-form/?case_id=16714 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm’s attorneys are ranked and recognized by numerous independent and respected sources. Rosen Law Firm has secured hundreds of millions of dollars for investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.

——————————-

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40^th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
[email protected]
[email protected]
www.rosenlegal.com

The issuer is solely responsible for the content of this announcement.

https://platform.twitter.com/widgets.js

Source link

This content was prepared by Media OutReach. The opinions expressed in this article are the author's own and do not reflect the view of Siam News Network.

KT&G to establish a new factory in Kazakhstan that will serve as a Global Manufacturing Innovation Hub

CISION PR Newswire

Oct 12, 2023

KT&G held a groundbreaking ceremony for its new state-of-art manufacturing plant in Kazakhstan on October 11, 2023. The picture shows KT&G CEO Mr. Bok-In Baek (third from the right) and the Governor of Almaty Marat Sultangaziyev (second from the left) are posing for a photo at the ceremony.

Ongoing growth investments in the overseas business sector Reaffirming commitment to the company’s ‘Global Top-tier’ vision

SEOUL, South Korea, Oct. 12, 2023 /PRNewswire/ — KT&G Corporation ("KT&G") (KRX:033780) held a groundbreaking ceremony for its new state-of-art manufacturing plant in Kazakhstan on October 11, 2023. The new Kazakhstan factory is expected to serve as the company’s Manufacturing Innovation Hub in Eurasia and accelerate the company’s long-term vision of becoming a ‘Global Top-tier’ company.

The groundbreaking ceremony took place at the site of the new factory in Almaty Province, Kazakhstan, and was attended by over 70 key figures, including KT&G CEO Bok-In Baek, Governor of Almaty Marat Sultangaziyev, Korean Consul General in Almaty Nae-cheon Park, and others.

KT&G’s new Kazakhstan factory, spanning approximately 200,000m2 , will function as a hybrid production facility, accommodating both Next Generation Product("NGP") and conventional cigarette("CC") production and addressing export demands across the Eurasian region.

KT&G positions Kazakhstan as a key growth hub for strengthening its global export competitiveness. KT&G has been committed to building a strong local business presence in Kazakhstan by establishing local sales and manufacturing subsidiaries in January, 2023. Moving forward, KT&G plans to increase its global business capabilities and profitability by managing the entire value chain locally, from production to marketing and sales.

The construction of the new Kazakhstan factory is part of KT&G’s long-term growth investment plan, which was unveiled at its Future Vision Declaration Ceremony held in January, 2023. At the ceremony, KT&G outlined its growth strategy to develop NGP, overseas CC, and Health Functional Food as its three core business areas. The company also shared its plans to increase the proportion of its overseas sales revenue to over 50% of its total sales revenue by 2027.

KT&G has also executed growth investments in Indonesia in September, 2023. The company conducted an investment support ceremony with the Indonesian Ministry of Investment and obtained an investment support letter with respect to the establishment of its new manufacturing plant in East Java province, Indonesia.

With this contemplated investment, KT&G strives to strategically position Indonesia as an export hub for the Southeast Asian market. In addition to having the Indonesian factory serving as an export hub for the Southeast Asian market, the company will utilize the Kazakhstan factory as a pivotal gateway for its Eurasian business expansion. The establishment of these two global production hubs is anticipated to strengthen KT&G’s presence in both Southeast Asian and Eurasian markets, aligning with the company’s ‘Global Top-tier’ vision.

KT&G CEO Bok-In Baek stated, "We expect the new Kazakhstan factory to serve as a core global production hub that encompasses the Eurasian market and become a frontline base for realizing our future vision of leaping forward to the ‘Global Top-tier’ status. We will continue to capture new business opportunities and increase our competitiveness through continued vigorous investments in our core business areas."

KT&G held a groundbreaking ceremony for its new state-of-art manufacturing plant in Kazakhstan on October 11, 2023. The picture shows KT&G CEO Mr. Bok-In Baek (third from the right) and the Governor of Almaty Marat Sultangaziyev (second from the left) are posing for a photo at the ceremony.

Source : KT&G to establish a new factory in Kazakhstan that will serve as a Global Manufacturing Innovation Hub

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages AeroVironment, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – AVAV

Corporate News Media OutReach

Oct 12, 2023

NEW YORK, NEW YORK – Newsfile Corp. – 11 October 2023 – WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of AeroVironment, Inc. (NASDAQ: AVAV) between June 29, 2021 and December 7, 2021, both dates inclusive (the “Class Period”), of the important October 30, 2023 lead plaintiff deadline.

SO WHAT: If you purchased AeroVironment securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the AeroVironment class action, go to https://rosenlegal.com/submit-form/?case_id=18820 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than October 30, 2023. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

DETAILS OF THE CASE: According to the lawsuit, the defendants made false and/or materially misleading statements by creating the false impression that they possessed reliable information pertaining to the Company’s projected growth and record backlog and also minimized any risk from COVID-19 (coronavirus), specifically explaining they were monitoring supply chain issues and affirmed their record backlog would provide a basis for strong growth. However, according to the lawsuit, AeroVironment had been experiencing a decline in sales in all of their core businesses. According to the lawsuit, defendants misled investors by providing the public with materially flawed revenue guidance for fiscal 2022. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the AeroVironment class action, go to https://rosenlegal.com/submit-form/?case_id=18820 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

——————————-

Contact Information:

The issuer is solely responsible for the content of this announcement.

https://platform.twitter.com/widgets.js

Source link

This content was prepared by Media OutReach. The opinions expressed in this article are the author's own and do not reflect the view of Siam News Network.